Silva, Aline David; Esteves, João Victor Del Conti 
; Morais, Mychel Raony Paiva Teixeira ; Freitas, Helayne Soares ; Zorn, Telma Maria Tenório; Giannella, Maria Lucia Cardillo Correa ; Machado, Ubiratan Fabres
Fonte: Diabetes, Metabolic Syndrome and Obesity. Unidades: ICB, FM
Assuntos: FISIOLOGIA, BIOLOGIA CELULAR, DIABETES MELLITUS, GLICOSE, GLICEMIA, HOMEOSTASE, CAMUNDONGOS, INFLAMAÇÃO, HEPATOPATIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Aline David et al. Dual SGLT1/SGLT2 inhibitor phlorizin ameliorates non-alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice. Diabetes, Metabolic Syndrome and Obesity, v. 2020, p. 739—751, 2020Tradução . . Disponível em: https://doi.org/10.2147/DMSO.S242282. Acesso em: 30 set. 2024.APA
Silva, A. D., Esteves, J. V. D. C., Morais, M. R. P. T., Freitas, H. S., Zorn, T. M. T., Giannella, M. L. C. C., & Machado, U. F. (2020). Dual SGLT1/SGLT2 inhibitor phlorizin ameliorates non-alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice. Diabetes, Metabolic Syndrome and Obesity, 2020, 739—751. doi:10.2147/DMSO.S242282NLM
Silva AD, Esteves JVDC, Morais MRPT, Freitas HS, Zorn TMT, Giannella MLCC, Machado UF. Dual SGLT1/SGLT2 inhibitor phlorizin ameliorates non-alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice [Internet]. Diabetes, Metabolic Syndrome and Obesity. 2020 ; 2020 739—751.[citado 2024 set. 30 ] Available from: https://doi.org/10.2147/DMSO.S242282Vancouver
Silva AD, Esteves JVDC, Morais MRPT, Freitas HS, Zorn TMT, Giannella MLCC, Machado UF. Dual SGLT1/SGLT2 inhibitor phlorizin ameliorates non-alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice [Internet]. Diabetes, Metabolic Syndrome and Obesity. 2020 ; 2020 739—751.[citado 2024 set. 30 ] Available from: https://doi.org/10.2147/DMSO.S242282
